US stocks are sharply down on Monday as Brexit news sparked a sell-off on Friday, sending the markets deep in the red. The Dow Jones Industrial Average has plummeted more than 300 points and no sign of improvement in the market sentiment is in sight as on Monday all three major indexes have been losing ground since the opening bell.
However, Vista Gold Corp. (NYSEMKT:VGZ), GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Barrick Gold Corporation (USA) (NYSE:ABX), Suffolk Bancorp (NYSE:SCNB) and Skullcandy Inc (NASDAQ:SKUL) are gaining ground today. Let’s find out why these stocks are up and see what the investors tracked by us think about them.
We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).
Vista Gold Surges Along with Gold Prices
Vista Gold Corp. (NYSEMKT:VGZ)’s stock has surged by over 17% so far today. The stock has been showing high volume of activity since Friday amid a jump in gold prices following the Brexit news. Only three hedge funds from our database were bullish on Vista Gold Corp. (NYSEMKT:VGZ) at the end of the first quarter, including Peter Franklin Palmedo’s Sun Valley Gold, which owns approximately 14.61 million shares of the company.
GW Pharmaceuticals Announces Positive Results of Epidiolex Drug
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)’s stock has jumped 10.27% so far today after the company announced positive results of a clinical trial of its investigational medicine Epidiolex for the treatment of Lennox-Gastaut syndrome (LGS), a severe form of epilepsy. The drug achieved a primary endpoint as it reduced the frequency of drop seizures. The trial was started after the company announced positive results of Epidiolex’s Phase 3 trial for the treatment of Dravet syndrome back in March. The drug currently has “Orphan” status, assigned by the FDA. A total of 18 hedge funds from our database amassed around $193.5 million worth of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares at the end of the first quarter of 2016.
On the next page, we talk about why Barrick Gold, Suffolk Bancorp and Skullcandy are gaining value today.